Author:
Hennessy Sean,Strom Brian L.,Berlin Jesse A.,Brennan Patrick J.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis againstPneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1993;6:46–55.
2. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis forPneumocystis carinii pneumonia in AIDS. JAMA. 1988; 259:1185–9.
3. Kennedy CA, Pimentel JA, Lewis DE, Anderson MD, Weiss PJ, Old- field EC. Crossover of human immunodeficiency virus—infected patients from aerosolized pentamidine to trimethoprim— sulfamethoxazole: lack of hematologic toxicity and a relationship of side effects to CD4+ lymphocyte count. J Infect Dis. 1993;168:314–7.
4. MacGregor RR, Morgan AS, Graziani AL, et al. Efficacy and tolerance of intermittent versus daily cotrimoxazole for PCP prophylaxis in HIV-positive patients. Am J Med. 1992;92:227–9.
5. Wormser GP, Horowitz HW, Duncanson FP, et al. Low-dose intermittent trimethoprim- sulfamethoxazole prevention ofPneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med. 1991; 151:688–92.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献